Philip Morris International

Designing a 
Smoke-Free Future

How long will PMI be in the cigarette business?

READ MORE
Careers at PMI
Investor Relations
Media Center

Why can't we talk about our better alternatives?

Learn more

Unsmoke Your World

Read more
Currently, regulations in many countries make it hard for smokers to have access to information about #smokefree products. We believe peo...
How much do you really know about nicotine? 🤔 If you ask the person on the street, you might get a lot of conflicting views But here a...
All News
s-i-home
Science & Innovation

Pioneering the way to a smoke-free future

We're at the forefront of developing less harmful alternatives to cigarettes.

Read more
A leading international tobacco company

Six of the world’s top 15 international brands are ours, including Marlboro, the world’s number one.

view more
Discover our smoke-free product portfolio

Millions of smokers have already switched to the first of our new products.

view more
Reporting on Sustainability

For PMI, sustainability means creating long-term value while minimizing the negative externalities associated with our products, operations and value chain.

view more

 

This site is operated for the purpose of providing general information about us. The site is not operated for advertising or marketing purposes. The material on this site should not be regarded as an offer to sell, or a solicitation of an offer to buy, any product of PMI. Such products are sold only in compliance with the laws of the particular jurisdictions in which they are sold. IQOS and other smoke-free products under development by PMI are not currently available in the U.S. . PMI has now been granted authorization to market IQOS 2.4 in the U.S. from the Food and Drug Administration (FDA), which Altria will bring to the U.S. market under the terms of a license from PMI. The FDA has not yet determined whether IQOS 2.4 meets the standard to be marketed in the U.S. as a modified risk tobacco product.  PMI’s applications to the FDA seeking authorization to market IQOSin the U.S. as a modified risk product are currently under review.